The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota

Last updated: July 5, 2023
Sponsor: Peter Humaidan
Overall Status: Active - Recruiting

Phase

2

Condition

Infertility

Treatment

Placebo

Clindamycin

Clinical Study ID

NCT05166746
AVM_Lacto_2015/582
  • Ages 18-42
  • Female

Study Summary

Study question: Does antibiotic alone or in combination with live biotherapeutic treatment of an abnormal vaginal microbiota improve the reproductive outcomes of IVF couples?

Study hypothesis:

The investigator hypothesize that treatment of the reproductive tract pathogens and restoration of vaginal Lactobacillus will improve the reproductive outcomes of IVF patients.

What is known already? Ultra-deep sequencing methods enable the refinement of reproductive tract microbiology in infertile patients. A recent meta-analysis reported that 19% of infertile patients had abnormal vaginal microbiota Moreover, someone have detected the presence of a Gardnerella (G.) vaginalis dominated endometrial biofilm in 50% of non-infertile patients with abnormal vaginal microbiota undergoing curettage; thus the treatment of such an endometrial biofilm might play an important role for the endometrial receptivity and subsequently the clinical pregnancy rate.

Pilot study: In a recent pilot study it was observed that an abnormal vaginal microbiota negatively affects the clinical pregnancy rate in IVF patients. In this study the prevalence of abnormal vaginal microbiota was 28% (36/130) and only 9% of patients with qPCR defined abnormal vaginal microbiota obtained a clinical pregnancy (p=0.004). This association remained significant in an adjusted analysis. Furthermore, the invetigators have preliminary results demonstrating that vaginal bacteria such as G. vaginalis can be found in the endometrium of IVF patients, which is also supported by recent publications

What is the novelty of this study? To the investigators knowledge, no previous treatment study of abnormal reproductive tract microbiota has been performed in IVF patients; this relatively small intervention holds the potential to increase the baby-take-home rate after IVF treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Abnormal vaginal microbiota.
  • The screening swab should be repeated if more than 3 months old.
  • HIV, Hepatitis B or C positivity.
  • First, second or third IVF stimulation cycle or embryo transfer therefrom.
  • BMI<35
  • Written informed consent.

Exclusion

Exclusion Criteria:

  • Known or suspected hypersensitivity to clindamycin.
  • HPV CIN 2 or higher.
  • Former or current inflammatory bowel disease
  • Severe concomitant disease, including diabetes.
  • MAX 2 embryos may be transferred
  • Artificial heart valve
  • Intrauterine malformations with operation indication as determined by treatingphysician (Polyps, Septum, fibroma)

Study Design

Total Participants: 333
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
December 07, 2017
Estimated Completion Date:
October 01, 2023

Connect with a study center

  • Copenhagen University Hospital, Rigshospitalet

    Copenhagen, 2100
    Denmark

    Active - Recruiting

  • Stork Fertility Clinic VivaNeo

    Copenhagen, 2100
    Denmark

    Active - Recruiting

  • Hvidovre Hospital, The Fertility Clinic

    Hvidovre, 2650
    Denmark

    Active - Recruiting

  • Fertility Clinic Skive, Skive Regional Hospital

    Skive, 7800
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.